enlightenbio  Blog

Monthly Industry News

Find here a listing of the latest industry news in genomics, genetics, precision medicine, and beyond. We will update and add to this page on a regular basis. This page is not a compilation of all relevant information but rather contains some key highlights that we consider to be of importance to share with the community.

Sign-Up for our newsletter and never miss out on the latest news and updates.

News for the month of March 2021

COVID-19 / SARS-CoV-2

Funding

Mergers & Acquisitions

Precision Medicine

CRISPR-Cas9 Genome Editing

Spatial Transcriptomics

Miscellaneous

Publications

News for the month of February 2021

February brought on an interesting series of SPACs in the genomics sector – if you are not familiar with this term, it means Special Purpose Acquisition Company which translates into a company going public via a merger. 23andMe, Nautilus Biotechnology, and Sema4 all went public via a SPAC. 23andMe merged with Virgin Groups VG Acquisition Corp [the business combination values 23andMe at an enterprise value of ~$3.5B], Nautilus Biotechnology merged with Arya Sciences Acquisition Corp III [the combined company is expected to receive proceeds of approximately $350M at the closing of the transaction], while Sema4 combined with CM Life Sciences [the combined company is expected to receive proceeds of up to ~$793M at the closing of the transaction, up to $343M of which will be paid to Sema4 stockholders and the remainder of which will be utilized by Sema4 for its business to be operated under the same Sema4 management team].

COVID-19 / SARS-CoV-2

Funding

Mergers & Acquisitions

Precision Medicine

Genomics / Genetic Testing

NGS / Genomics Platforms

Liquid Biopsy

Artificial Intelligence / Machine Learning

Immunotherapy

CRISPR-Cas9 Genome Editing 

Miscellaneous

Publication

News for the month of January 2021

During the month of January, attention was primarily directed towards the new SARS-CoV-2 variants (especially the ones that emerged from the U.K., South Africa, and Brazil). We’ve learned that these new variants have been more transmissible compared to the original virus, resulting in greater danger of risk of higher numbers in hospitalizations and deaths. In hopes of expanding the country’s surveillance to detect and characterize emerging variants of SARS-CoV-2 Illumina and Helix started a collaboration to augment national surveillance infrastructure, while Quest Diagnostics was granted a CDC contract to sequence COVID-19 gene variants to identify new mutations and patterns of SARS-CoV-2 transmission.

Other notable developments include announcements that took place during the JP Morgan Healthcare conference, such as the multi-year PacBio-Invitae collaboration to develop a production-scale, high-throughput clinical whole genome sequencing platform leveraging the power of PacBio’s HiFi sequencing technology, as well as Illumina’s launch of Illumina Connected Analytics (ICA), a cloud-based platform for multi-omics data exploration, coupled with machine learning, and tertiary analysis tools which harnesses the DRAGEN Bio-IT Platform (acquired in 2018) and BlueBee technology (acquired in 2020). 

COVID-19 / SARS-CoV-2

For more in-depth reading, our compiled COVID-19/SARS-CoV-2 news page lists selected coronavirus/COVID-19 news.

Funding

Mergers, Acquisitions, and Partnerships

Precision Medicine

Genomic / Genetic Testing

NGS / Genomics Platforms

CRISPR-Cas9 Genome Editing 

Artificial Intelligence / Machine Learning

Microbiome

Miscellaneous

Publications

Following are archived industry news

Industry News – 2020

Industry News – 2019

Industry News – 2018

Industry News – 2017

ADVERTISEMENT

Follow Me

%d bloggers like this: